Diffusion Pharmaceuticals Inc. (DFFN) 7.3000 $DFFN

Diffusion Pharmaceuticals Inc. (DFFN) 7.3000 $DFFN

Diffusion Pharmaceuticals Successfully Completes Animal Toxicity Studies in Preparation for Phase 3 Pivotal Trial of TSC in New Diagnosed Glioblastoma Patients
GlobeNewswire - Mon Sep 19, 7:30AM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today reported the successful completion of dosing of two animal toxicology studies required by the U.S. Food and Drug Administration (FDA) to support Diffusion's planned Phase 3 clinical trial testing its lead molecule trans sodium crocetinate (TSC) in newly diagnosed Glioblastoma (GBM) patients.

Diffusion Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Fri Sep 09, 7:30AM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFND), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to be held September 11-13, 2016 in New York, NY.

Diffusion Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
GlobeNewswire - Thu Aug 18, 7:30AM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today announced that its Board of Directors approved an amendment to the Company's certificate of incorporation effecting a 1-for-10 reverse split of all outstanding common stock. Diffusion's stockholders previously approved the reverse split on July 21, 2016. Both the record date and effective date for the reverse stock split will be August 17, 2016 and, following the reverse split, Diffusion intends to uplist to the NASDAQ Capital Market.

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Second Quarter 2016 Results
GlobeNewswire - Mon Aug 15, 3:15PM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today reported financial results for the three months ended June 30, 2016 and provided an overview of recent corporate highlights. The results will be filed shortly on the Quarterly Report on Form 10-Q with the SEC.

Diffusion Pharmaceuticals Appoints Biotech Industry Veteran Isaac Blech to Board of Directors
GlobeNewswire - Mon Aug 15, 3:10PM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced the appointment of Isaac Blech to its Board of Directors, effective August 10, 2016, as Vice Chairman of the Board.

Diffusion Pharmaceuticals Expands Patent Estate of TSC as Therapeutic in Five Hypoxia-Related Indications
GlobeNewswire - Wed Jun 08, 7:30AM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that a U.S. patent application, entitled "Bipolar Trans Carotenoid Salts and Their Uses," was allowed by the United States Patent and Trademark Office.

Diffusion Pharmaceuticals to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at the JMP Securities Life Sciences Conference to be held June 21- 22, 2016 in New York, NY.

Diffusion Pharmaceuticals Announces Publication of TSC Phase 1/2 Glioblastoma Multiforme Trial Data in the Journal of Neurosurgery
GlobeNewswire - Fri May 13, 10:45AM CDT
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that data from the Phase 1/2 clinical trial evaluating the safety and efficacy of trans sodium crocetinate (TSC) in newly diagnosed glioblastoma multiforme (GBM) has been published online today in the Journal of Neurosurgery ("JNS", the official publication of the American Association of Neurological Surgeons. As outlined in the JNS article, 36.3% of the full TSC dose patients were alive at two years based on a Kaplan-Meier analysis, compared to reported survival rates for the standard of care (SOC) ranging from 27% to 30%. TSC, the Company's lead product candidate, is designed to target the tumor's hypoxic microenvironment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of SOC radiation therapy and chemotherapy.

Diffusion Pharmaceuticals Announces Presentation at BIO CEO & Investor Conference
GlobeNewswire - Tue Jan 26, 7:31AM CST
Diffusion Pharmaceuticals Inc. (OTCQXFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at the BIO CEO & Investor Conference to be held February 8 - 9, 2016 in New York, NY.

Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN
GlobeNewswire - Mon Jan 25, 6:30AM CST
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Markets under the trading symbol "DFFN" (OTCQXFFN). The previous trading symbol was "RESX" (OTCQX:RESX).